La Malattia di La Peyronie: una complicanza delle uretriti

Backgraund. Peyronie’s disease (PD) arises after an inflammatory process on tunica albuginea. This produces on corpus cavernosum fibrocalcific plaques, microvascularization around plaques, pain and recurvatio penis. Ultrasound test (US) can define the PD activity into 4 stages with a growing clinic importance. PD is decribed in patients with hypermobile syndrome and penile asimmetrical traumas. We described the onset of PD in patients with urethral diseases and the benefit effects of the pharmacological antinflammatory therapy. Patients and Methods. 24 patients, aged 37-51 years (middle age 45 years) were enrolled in this study. Patients showed since 12-26 months chronic urethral diseases (mycosis, urethritis, condyloma acuminatum, traumas) and since 6-12 months the PD. The PD was confirmed by ultrasound (US) test (7,5 and 10 MHz linear probes). Patients was treated, during a 4 month period, with pharmacological anti-inflammatory therapy. Results. Before therapy: 10 patients show PD with I stage, 6 patients PD with II stage. Last therapy PD was absent in 9 patients, while 4 patients show PD with 0 stage, 2 patients PD with I stage and in 1 patient PD with II stage. Discussion. Chronic urethral diseases cause the inflammatory process. This involves corpus cavernosum and produces the microvascularization, plaques and symptoms. The pharmacological anti-inflammatory therapy showes a 81,25% reduction in clinical signs and in activity of PD.